These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23713182)

  • 1. [Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)].
    Perusicová J; Haladová I; Pit'hová P; Acsová D; Belobrádková J; Belzová A; Berková K; Dolezalová B; Dvoráková H; Hejnicová K; Hudcová M; Kallmünzerová D; Krejsová Z; Markofová G; Müllerová H; Owen K; Pelikánová M; Raclavská L; Racická E; Skarpová O; Váchová A; Veselá A; Vyoralos J; Broz J; Edelsberger T; Honka M; Hrdina T; Chmura P; Tosovský J
    Vnitr Lek; 2013 Mar; 59(3):165-71. PubMed ID: 23713182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic -  BIBYII study (observations lasting 24 months)].
    Perušičová J; Piťhová P; Haladová I; Diabetologů AP; Acsová D; Bělobrádková J; Belzová A; Berková K; Doležalová B; Dvořáková H; Hejnicová K; Hudcová M; Kallmünzerová D; Krejsová Z; Markofová G; Müllerová H; Owen K; Pelikánová M; Raclavská L; Račická E; Skarpová O; Váchová A; Veselá A; Vyoralová J; Brož J; Edelsberger T; Honka M; Hrdina T; Chmura P; Tosovsky J
    Vnitr Lek; 2013 Apr; 59(4):249-55. PubMed ID: 23711049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.
    Buysschaert M; Preumont V; Oriot PR; Paris I; Ponchon M; Scarnière D; Selvais P;
    Diabetes Metab; 2010 Nov; 36(5):381-8. PubMed ID: 20598606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM; Cavaghan MK; Brunelle RL; Roach P
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
    Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
    Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
    Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with exenatide in a routine secondary care diabetes clinic.
    Natarajan B; Edavalath M; Davies J; Jenkins L; Marshall-Richards N; Evans D; Price DE; Bain SC; Stephens JW
    Prim Care Diabetes; 2010 Apr; 4(1):57-60. PubMed ID: 20022310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
    Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
    Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
    Paul S; Best J; Klein K; Han J; Maggs D
    Diabetes Obes Metab; 2012 Sep; 14(9):826-34. PubMed ID: 22510305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.
    Preumont V; Hermans MP; Brichard S; Buysschaert M
    Diabetes Metab; 2010 Sep; 36(4):293-8. PubMed ID: 20447851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.
    Forti A; Garcia EG; Yu MB; Jimenez MC; Brodows RG; Oliveira JH
    Curr Med Res Opin; 2008 Sep; 24(9):2437-47. PubMed ID: 18662495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study].
    De Block C; Paquot N; Daoudi N; Ballaux D; Van Gaal LF; Scheen AJ
    Rev Med Liege; 2009 Oct; 64(10):488-95. PubMed ID: 19911661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes.
    Schernthaner G; Guerci B; Gallwitz B; Rose L; Nicolay C; Kraus P; Kazda C
    Diabetes Metab; 2010 Nov; 36(5):389-94. PubMed ID: 20598608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control and weight changes in patients with type 2 diabetes intensified to three insulin regimens after therapeutic failure to exenatide.
    Buysschaert M; Paris I; Selvais P; Oriot P; Preumont V;
    Acta Clin Belg; 2012; 67(4):250-4. PubMed ID: 23019799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.